View Older Stories View More Recent Stories

Jun 25, 2018 09:04AM AbbVie (ABBV) Says IMBRUVICA sNDA Accepted for Review by FDA with Potential to Broaden Treatment Use as Combination Treatment Option with Rituximab in WM
Jun 25, 2018 09:00AM IMBRUVICA® (ibrutinib) Supplemental New Drug Application Accepted for Review by U.S. FDA with Potential to Broaden Treatment Use as a Combination Treatment Option with Rituximab in Waldenström's Mac
Jun 25, 2018 07:01AM AbbVie (ABBV) Reports Pact with Calibr for next generation T-cell Therapies
Jun 25, 2018 07:00AM AbbVie and Calibr announce collaboration for next generation T-cell therapies
Jun 19, 2018 09:21AM 8,000 AbbVie Employees Volunteer Across Five Continents During Fifth-Annual "Week of Possibilities"
Jun 15, 2018 05:42AM AbbVie (ABBV) Highlights Data from Phase 3 Relapsed/Refractory Chronic Lymphocytic Leukemia MURANO Trial of Venetoclax in Combination with Rituximab
Jun 15, 2018 02:45AM AbbVie Announces New Undetectable Minimal Residual Disease Data from Phase 3 Relapsed/Refractory Chronic Lymphocytic Leukemia MURANO Trial of Venetoclax in Combination with Rituximab at 23rd European
Jun 14, 2018 06:52PM AbbVie Declares Quarterly Dividend
Jun 13, 2018 05:49AM AbbVie (ABBV) Highlights Additional Outcomes Data from Three Upadacitinib Phase 3 Studies in Rheumatoid Arthritis at EULAR 2018
Jun 12, 2018 06:38PM AbbVie Presents Additional Outcomes Data from Three Upadacitinib Phase 3 Studies in Rheumatoid Arthritis at the Annual European Congress of Rheumatology (EULAR 2018)
Jun 8, 2018 02:56PM AbbVie (ABBV) Confirms FDA Approval of VENCLEXTA in Combination with Rituximab for Treatment of CLL or SLL
Jun 8, 2018 02:55PM AbbVie Announces U.S. FDA Approval of VENCLEXTA® (venetoclax tablets) in Combination with Rituximab as a Fixed Duration Treatment for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Patien
Jun 5, 2018 08:36AM UPDATE: AbbVie (ABBV) Reports Upadacitinib Monotherapy Meets All Primary & Ranked Secondary Endpoints Versus Methotrexate in a Phase 3 Study
Jun 5, 2018 08:30AM Upadacitinib Monotherapy Meets All Primary and Ranked Secondary Endpoints Versus Methotrexate in a Phase 3 Study in Rheumatoid Arthritis
Jun 4, 2018 08:00AM AbbVie (ABBV) Announces Final Results of Tender Offer
Jun 4, 2018 08:00AM AbbVie Announces Final Results of Tender Offer
Jun 4, 2018 06:40AM AbbVie (ABBV) Repots Positive Data from Phase 2 CAPTIVATE (PCYC-1142) Study Evaluating IMBRUVICA (ibrutinib) in Combination with VENCLEXTA (venetoclax)
Jun 3, 2018 10:45AM Phase 2 IMBRUVICA® (ibrutinib) Plus VENCLEXTA® (venetoclax) Early Data Show High Rates of Responses in Patients with Previously-Untreated Chronic Lymphocytic Leukemia (CLL)
Jun 1, 2018 05:00PM AbbVie (ABBV) Reports Phase 3 IMBRUVICA (ibrutinib) Data Suggest Improved Treatment Outcomes in Waldenstrom's Macroglobulinemia in Combination with Rituximab
Jun 1, 2018 04:45PM Phase 3 IMBRUVICA® (ibrutinib) Data Suggest Improved Treatment Outcomes in Waldenström's Macroglobulinemia (WM), a Rare Form of Blood Cancer, in Combination with Rituximab versus Rituximab Alone
May 31, 2018 08:08AM AbbVie (ABBV) to Present New Data from Studies of Venetoclax as Monotherapy or in Combination for Management of Difficult-to-Treat Blood Cancers at EHA
May 31, 2018 08:00AM AbbVie to Present New Data from Several Investigational Studies of Venetoclax as Monotherapy or in Combination for the Management of a Number of Difficult-to-Treat Blood Cancers at 23rd European Hemat
May 30, 2018 05:18PM UPDATE: AbbVie (ABBV) Updates Preliminary Results of Tender Offer; Expects to Acquire 72.8M Shares at $103 Per Share
May 30, 2018 04:46PM AbbVie Announces Updated Preliminary Results of Tender Offer
May 30, 2018 08:10AM AbbVie (ABBV) Says Preliminary Proration Factor for Tender Offer is Approximately 94.3%
May 30, 2018 08:00AM AbbVie Announces Preliminary Results of Tender Offer
May 29, 2018 08:00AM AbbVie to Present at the Goldman Sachs 39th Annual Global Healthcare Conference
May 24, 2018 09:02AM AbbVie (ABBV) Reports IMBRUVICA (ibrutinib) Plus GAZYVA (obinutuzumab) Phase 3 iLLUMINATE (PCYC-1130) Trial Met Primary Endpoint of Improvement in Progression-Free Survival
May 24, 2018 09:00AM IMBRUVICA® (ibrutinib) Plus GAZYVA® (obinutuzumab) Phase 3 iLLUMINATE Trial for First-Line Therapy of Chronic Lymphocytic Leukemia (CLL) Patients Met Primary Endpoint
May 22, 2018 10:30AM AbbVie Donates $100 Million to Strengthen Access to Healthcare, Housing for Hurricane-Ravaged Puerto Rico
May 22, 2018 08:00AM AbbVie to Present at the Jefferies 2018 Global Healthcare Conference
May 16, 2018 04:59PM AbbVie (ABBV) to Show Progress and Growth in Oncology Research at ASCO
May 16, 2018 04:59PM AbbVie to Show Progress and Growth in Oncology Research at the American Society of Clinical Oncology 2018 Annual Meeting
May 8, 2018 08:00AM AbbVie to Present at the UBS Global Healthcare Conference
May 2, 2018 08:00AM AbbVie to Present at the 2018 Bank of America Merrill Lynch Health Care Conference
May 1, 2018 08:46AM AbbVie (ABBV) Submits MAA to EMA for Investigational Treatment Risankizumab for Moderate to Severe Plaque Psoriasis
May 1, 2018 08:45AM AbbVie Submits Marketing Authorization Application to the European Medicines Agency for Investigational Treatment Risankizumab for Moderate to Severe Plaque Psoriasis
May 1, 2018 07:47AM AbbVie (ABBV) Commences Self-Tender Offer for Up to $7.5 Billion of its Common Stock
May 1, 2018 07:47AM AbbVie Commences Self-Tender Offer for Up to $7.5 Billion of its Common Stock
Apr 30, 2018 11:35AM AbbVie and Rice University establish K.C. Nicolaou Research Accelerator to advance therapies in oncology
Apr 27, 2018 08:10AM AbbVie (ABBV) Highlights New Investigational Data for Elagolix at 2018 ACOG Meetings
Apr 27, 2018 08:00AM AbbVie Presents New Investigational Data for Elagolix at the 2018 American College of Obstetricians and Gynecologists (ACOG) Annual Meeting
Apr 26, 2018 07:47AM AbbVie Reports First-Quarter 2018 Financial Results
Apr 25, 2018 08:45AM AbbVie (ABBV) Submits BLA to FDA for Investigational Treatment Risankizumab for Moderate to Severe Plaque Psoriasis
Apr 25, 2018 08:45AM AbbVie Submits Biologics License Application to U.S. FDA for Investigational Treatment Risankizumab for Moderate to Severe Plaque Psoriasis
Apr 25, 2018 08:36AM AbbVie (ABBV) Says Upadacitinib Met Primary and Key Efficacy Endpoints in Phase 2b/3 RA Study in Japanese Patients
Apr 25, 2018 08:30AM AbbVie's Upadacitinib Meets Primary and Key Efficacy Endpoints in Phase 2b/3 Rheumatoid Arthritis Study in Japanese Patients
Apr 18, 2018 08:00AM AbbVie to Present at the Deutsche Bank's 43rd Annual Health Care Conference
Apr 10, 2018 08:15AM AbbVie (ABBV), Neurocrine Biosciences (NBIX) Announce PDUFA Target Date of Q3 2018 for Elagolix in Endometriosis-Associated Pain
Apr 10, 2018 08:15AM AbbVie and Neurocrine Biosciences Announce PDUFA Target Date of Q3 2018 for Elagolix in Endometriosis-Associated Pain
View More Recent Stories View Older Stories